Find Ruxolitinib Phosphate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1092939-17-7, Jakafi, (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, Jakavi, Ruxolitinib (phosphate), Ruxolitinib monophosphate
Molecular Formula
C17H21N6O4P
Molecular Weight
404.4  g/mol
InChI Key
JFMWPOCYMYGEDM-XFULWGLBSA-N
FDA UNII
436LRU32H5

Ruxolitinib Phosphate
Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
1 2D Structure

Ruxolitinib Phosphate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
2.1.2 InChI
InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
2.1.3 InChI Key
JFMWPOCYMYGEDM-XFULWGLBSA-N
2.1.4 Canonical SMILES
C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
2.1.5 Isomeric SMILES
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
2.2 Other Identifiers
2.2.1 UNII
436LRU32H5
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile

2. Inc-424

3. Inc424

4. Inca24

5. Incb-018424

6. Incb-018424 Phosphate

7. Incb-018424 Salt

8. Incb-18424

9. Incb-18424 Phosphate

10. Incb018424

11. Incb018424 Phosphate

12. Jakafi

13. Jakavi

14. Opzelura

15. Ruxolitinib

16. Ruxolitinib (as Phosphate)

17. Ruxolitinib Monophosphate

2.3.2 Depositor-Supplied Synonyms

1. 1092939-17-7

2. Jakafi

3. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Phosphate

4. Jakavi

5. Ruxolitinib (phosphate)

6. Ruxolitinib Monophosphate

7. Incb018424 Phosphate

8. Ruxolitinib (as Phosphate)

9. Incb-018424 Phosphate

10. Incb-018424 Salt

11. Ruxolitinib Phosphate [usan]

12. Incb-18424 Phosphate

13. Incb018424 Salt

14. Chebi:66917

15. 436lru32h5

16. 1092939-17-7 (phosphate)

17. (betar)-beta-cyclopentyl-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazole-1-propanenitrile Phosphate

18. Incb-18424

19. Ruxolitinib Phosphate Salt

20. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile Phosphate

21. (3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)

22. Phosphenoperoxoic Acid Compound With (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)- 1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile And Dihydrogen (1:1:1)

23. Opzelura

24. Unii-436lru32h5

25. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrilephosphoricacid

26. Jakafi (tn)

27. Jakavi (tn)

28. Ruxolitinib Phosphate(incb018424)

29. Inc 424 Phosphate

30. Incb 018424 Phosphate

31. Incb-424

32. Schembl1369365

33. Chembl1795071

34. Amy5620

35. Dtxsid00911086

36. Ruxolitinib Phosphate (jan/usan)

37. Ruxolitinib Phosphate [mi]

38. Ruxolitinib Phosphate [jan]

39. Ex-a2660

40. Cs1956

41. Mfcd18452860

42. S5243

43. Akos024464417

44. Ruxolitinib (incb-18424) Phosphate

45. Ruxolitinib Phosphate [who-dd]

46. Bcp9000783

47. Ccg-268687

48. Cs-0326

49. 1h-pyrazole-1-propanenitrile, Beta-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betar)-, Phosphate (1:1)

50. Ac-30901

51. As-74723

52. Hy-50858

53. Ruxolitinib Phosphate [orange Book]

54. Ruxolitinib (as Phosphate) [ema Epar]

55. D09960

56. J-501793

57. Q27135517

58. (3r)-3-cyclopentyl-3-(4-{7h-pyrrolo[2,3-d]pyrimidin-4-yl}-1h-pyrazol-1-yl)propanenitrile; Phosphoric Acid

59. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric Acid

60. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate

61. 1h-pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(.beta.r)-,phosphate (1:1)

62. Phosphoric Acid--3-cyclopentyl-3-[4-(1h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile (1/1)

2.4 Create Date
2009-01-19
3 Chemical and Physical Properties
Molecular Weight 404.4 g/mol
Molecular Formula C17H21N6O4P
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass404.13619017 g/mol
Monoisotopic Mass404.13619017 g/mol
Topological Polar Surface Area161 Ų
Heavy Atom Count28
Formal Charge0
Complexity503
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameJakafi
PubMed HealthRuxolitinib (By mouth)
Drug ClassesAntineoplastic Agent
Active IngredientRuxolitinib phosphate
Dosage FormTablet
RouteOral
Strengtheq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base
Market StatusPrescription
CompanyIncyte

2 of 2  
Drug NameJakafi
PubMed HealthRuxolitinib (By mouth)
Drug ClassesAntineoplastic Agent
Active IngredientRuxolitinib phosphate
Dosage FormTablet
RouteOral
Strengtheq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base
Market StatusPrescription
CompanyIncyte

4.2 Drug Indication

* Myelofibrosis (MF):

Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

* Polycythaemia vera (PV):

Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

* Graft versus host disease (GvHD):

Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5. 1).


Treatment of chronic Graft versus Host Disease (cGvHD)


Treatment of acute graft-versus-host disease (aGvHD)


Treatment of vitiligo


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EJ01


FDF Dossiers

read-more
read-more

01

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

02

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

03

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 15MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

04

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

05

Apotex Inc

Canada
AACR Annual meeting
Not Confirmed
arrow

Apotex Inc

Canada
arrow
AACR Annual meeting
Not Confirmed

Ruxolitinib

Brand Name : Ruxolitinib

Dosage Form : TABLET; ORAL

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number : 219660

Regulatory Info :

Registration Country : USA

blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 5MG BASE

Packaging :

Approval Date : 2011-11-16

Application Number : 202192

Regulatory Info : RX

Registration Country : USA

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 10MG BASE

Packaging :

Approval Date : 2011-11-16

Application Number : 202192

Regulatory Info : RX

Registration Country : USA

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 15MG BASE

Packaging :

Approval Date : 2011-11-16

Application Number : 202192

Regulatory Info : RX

Registration Country : USA

blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 20MG BASE

Packaging :

Approval Date : 2011-11-16

Application Number : 202192

Regulatory Info : RX

Registration Country : USA

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 25MG BASE

Packaging :

Approval Date : 2011-11-16

Application Number : 202192

Regulatory Info : RX

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

APOTEX

Canada
AACR Annual meeting
Not Confirmed
arrow

APOTEX

Canada
arrow
AACR Annual meeting
Not Confirmed

Ruxolitinib

Brand Name : Ruxolitinib

Dosage Form : TABLET; ORAL

Dosage Strength : 10MG

Approval Date :

Application Number : 219660

RX/OTC/DISCN :

RLD :

TE Code :

blank

02

APOTEX

Canada
AACR Annual meeting
Not Confirmed
arrow

APOTEX

Canada
arrow
AACR Annual meeting
Not Confirmed

Ruxolitinib

Brand Name : Ruxolitinib

Dosage Form : TABLET; ORAL

Dosage Strength : 15MG

Approval Date :

Application Number : 219660

RX/OTC/DISCN :

RLD :

TE Code :

blank

03

APOTEX

Canada
AACR Annual meeting
Not Confirmed
arrow

APOTEX

Canada
arrow
AACR Annual meeting
Not Confirmed

Ruxolitinib

Brand Name : Ruxolitinib

Dosage Form : TABLET; ORAL

Dosage Strength : 2MG

Approval Date :

Application Number : 219660

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

INCYTE CORP

U.S.A
AACR Annual meeting
Not Confirmed
arrow

INCYTE CORP

U.S.A
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 5MG BASE

Approval Date : 2011-11-16

Application Number : 202192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

05

INCYTE CORP

U.S.A
AACR Annual meeting
Not Confirmed
arrow

INCYTE CORP

U.S.A
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 10MG BASE

Approval Date : 2011-11-16

Application Number : 202192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

06

INCYTE CORP

U.S.A
AACR Annual meeting
Not Confirmed
arrow

INCYTE CORP

U.S.A
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 15MG BASE

Approval Date : 2011-11-16

Application Number : 202192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

07

INCYTE CORP

U.S.A
AACR Annual meeting
Not Confirmed
arrow

INCYTE CORP

U.S.A
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 20MG BASE

Approval Date : 2011-11-16

Application Number : 202192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

08

INCYTE CORP

U.S.A
AACR Annual meeting
Not Confirmed
arrow

INCYTE CORP

U.S.A
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : JAKAFI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 25MG BASE

Approval Date : 2011-11-16

Application Number : 202192

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

09

INCYTE CORP

U.S.A
AACR Annual meeting
Not Confirmed
arrow

INCYTE CORP

U.S.A
arrow
AACR Annual meeting
Not Confirmed

RUXOLITINIB PHOSPHATE

Brand Name : OPZELURA

Dosage Form : CREAM;TOPICAL

Dosage Strength : EQ 1.5% BASE

Approval Date : 2021-09-21

Application Number : 215309

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

01

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Ruxolitinib Phosphate

Dosage : Tablet

Dosage Strength : 5MG

Brand Name : Relata

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

02

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

02

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Ruxolitinib Phosphate

Dosage : Tablet

Dosage Strength : 10MG

Brand Name : Relata

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

03

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 15MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

03

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Ruxolitinib Phosphate

Dosage : Tablet

Dosage Strength : 15MG

Brand Name : Relata

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

04

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Ruxolitinib Phosphate

Brand Name : Relata

Dosage Form : Tablet

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

04

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Ruxolitinib Phosphate

Dosage : Tablet

Dosage Strength : 20MG

Brand Name : Relata

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Granulation

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Coating Systems & Additives

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Taste Masking

read-more
read-more

API Stability Enhancers

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1092939-17-7 / Ruxolitinib Phosphate API manufacturers, exporters & distributors?

Ruxolitinib Phosphate manufacturers, exporters & distributors 1

98

PharmaCompass offers a list of Ruxolitinib Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ruxolitinib Phosphate manufacturer or Ruxolitinib Phosphate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ruxolitinib Phosphate manufacturer or Ruxolitinib Phosphate supplier.

API | Excipient name

Ruxolitinib Phosphate

Synonyms

1092939-17-7, Jakafi, (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, Jakavi, Ruxolitinib (phosphate), Ruxolitinib monophosphate

Cas Number

1092939-17-7

Unique Ingredient Identifier (UNII)

436LRU32H5

About Ruxolitinib Phosphate

Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Jakavi Manufacturers

A Jakavi manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Jakavi, including repackagers and relabelers. The FDA regulates Jakavi manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Jakavi API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Jakavi manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Jakavi Suppliers

A Jakavi supplier is an individual or a company that provides Jakavi active pharmaceutical ingredient (API) or Jakavi finished formulations upon request. The Jakavi suppliers may include Jakavi API manufacturers, exporters, distributors and traders.

click here to find a list of Jakavi suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Jakavi USDMF

A Jakavi DMF (Drug Master File) is a document detailing the whole manufacturing process of Jakavi active pharmaceutical ingredient (API) in detail. Different forms of Jakavi DMFs exist exist since differing nations have different regulations, such as Jakavi USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Jakavi DMF submitted to regulatory agencies in the US is known as a USDMF. Jakavi USDMF includes data on Jakavi's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Jakavi USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Jakavi suppliers with USDMF on PharmaCompass.

Jakavi KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Jakavi Drug Master File in Korea (Jakavi KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Jakavi. The MFDS reviews the Jakavi KDMF as part of the drug registration process and uses the information provided in the Jakavi KDMF to evaluate the safety and efficacy of the drug.

After submitting a Jakavi KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Jakavi API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Jakavi suppliers with KDMF on PharmaCompass.

Jakavi WC

A Jakavi written confirmation (Jakavi WC) is an official document issued by a regulatory agency to a Jakavi manufacturer, verifying that the manufacturing facility of a Jakavi active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Jakavi APIs or Jakavi finished pharmaceutical products to another nation, regulatory agencies frequently require a Jakavi WC (written confirmation) as part of the regulatory process.

click here to find a list of Jakavi suppliers with Written Confirmation (WC) on PharmaCompass.

Jakavi NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Jakavi as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Jakavi API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Jakavi as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Jakavi and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Jakavi NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Jakavi suppliers with NDC on PharmaCompass.

Jakavi GMP

Jakavi Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Jakavi GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Jakavi GMP manufacturer or Jakavi GMP API supplier for your needs.

Jakavi CoA

A Jakavi CoA (Certificate of Analysis) is a formal document that attests to Jakavi's compliance with Jakavi specifications and serves as a tool for batch-level quality control.

Jakavi CoA mostly includes findings from lab analyses of a specific batch. For each Jakavi CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Jakavi may be tested according to a variety of international standards, such as European Pharmacopoeia (Jakavi EP), Jakavi JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Jakavi USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty